nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—TACR1—bipolar disorder	0.478	0.576	CbGaD
Paroxetine—SLC6A3—bipolar disorder	0.152	0.183	CbGaD
Paroxetine—SLC6A4—bipolar disorder	0.113	0.137	CbGaD
Paroxetine—HTR2A—bipolar disorder	0.0872	0.105	CbGaD
Paroxetine—SLC6A2—locus ceruleus—bipolar disorder	0.00734	0.132	CbGeAlD
Paroxetine—HTR2A—locus ceruleus—bipolar disorder	0.00441	0.0793	CbGeAlD
Paroxetine—SLC6A3—telencephalic ventricle—bipolar disorder	0.00431	0.0776	CbGeAlD
Paroxetine—SLC6A2—autonomic nervous system—bipolar disorder	0.0039	0.0702	CbGeAlD
Paroxetine—HTR2A—autonomic nervous system—bipolar disorder	0.00234	0.0422	CbGeAlD
Paroxetine—CYP2C9—urine—bipolar disorder	0.00232	0.0417	CbGeAlD
Paroxetine—HTR2A—telencephalic ventricle—bipolar disorder	0.00209	0.0376	CbGeAlD
Paroxetine—HTR2A—urine—bipolar disorder	0.00191	0.0344	CbGeAlD
Paroxetine—SLC6A4—blood plasma—bipolar disorder	0.00188	0.0339	CbGeAlD
Paroxetine—CYP2D6—urine—bipolar disorder	0.00174	0.0313	CbGeAlD
Paroxetine—CYP2C8—blood plasma—bipolar disorder	0.00136	0.0245	CbGeAlD
Paroxetine—CYP2B6—blood plasma—bipolar disorder	0.00122	0.022	CbGeAlD
Paroxetine—TACR1—nervous system—bipolar disorder	0.00122	0.0219	CbGeAlD
Paroxetine—CYP2C9—blood plasma—bipolar disorder	0.00121	0.0218	CbGeAlD
Paroxetine—CHRM4—nervous system—bipolar disorder	0.00114	0.0206	CbGeAlD
Paroxetine—HTR2A—blood plasma—bipolar disorder	0.000997	0.0179	CbGeAlD
Paroxetine—TACR1—brain—bipolar disorder	0.00093	0.0167	CbGeAlD
Paroxetine—CYP2D6—blood plasma—bipolar disorder	0.000909	0.0163	CbGeAlD
Paroxetine—CHRM5—nervous system—bipolar disorder	0.000894	0.0161	CbGeAlD
Paroxetine—CHRM4—brain—bipolar disorder	0.000874	0.0157	CbGeAlD
Paroxetine—CHRM5—brain—bipolar disorder	0.000683	0.0123	CbGeAlD
Paroxetine—ABCB1—blood plasma—bipolar disorder	0.000654	0.0118	CbGeAlD
Paroxetine—CYP2B6—adrenal cortex—bipolar disorder	0.000621	0.0112	CbGeAlD
Paroxetine—CHRM2—nervous system—bipolar disorder	0.000613	0.011	CbGeAlD
Paroxetine—SLC6A3—nervous system—bipolar disorder	0.000612	0.011	CbGeAlD
Paroxetine—CHRM3—thyroid gland—bipolar disorder	0.000594	0.0107	CbGeAlD
Paroxetine—SLC6A3—cerebellum—bipolar disorder	0.000576	0.0104	CbGeAlD
Paroxetine—SLC6A4—nervous system—bipolar disorder	0.000561	0.0101	CbGeAlD
Paroxetine—CHRM1—nervous system—bipolar disorder	0.000558	0.01	CbGeAlD
Paroxetine—CHRM3—nervous system—bipolar disorder	0.0005	0.00899	CbGeAlD
Paroxetine—SLC6A2—nervous system—bipolar disorder	0.000493	0.00887	CbGeAlD
Paroxetine—CHRM2—brain—bipolar disorder	0.000469	0.00843	CbGeAlD
Paroxetine—SLC6A3—brain—bipolar disorder	0.000468	0.00841	CbGeAlD
Paroxetine—SLC6A4—brain—bipolar disorder	0.000428	0.0077	CbGeAlD
Paroxetine—CHRM1—brain—bipolar disorder	0.000427	0.00768	CbGeAlD
Paroxetine—CHRM3—brain—bipolar disorder	0.000382	0.00687	CbGeAlD
Paroxetine—SLC6A2—brain—bipolar disorder	0.000377	0.00678	CbGeAlD
Paroxetine—CYP2B6—nervous system—bipolar disorder	0.000364	0.00654	CbGeAlD
Paroxetine—ABCB1—adrenal cortex—bipolar disorder	0.000332	0.00597	CbGeAlD
Paroxetine—CYP2C8—brain—bipolar disorder	0.00031	0.00557	CbGeAlD
Paroxetine—HTR2A—nervous system—bipolar disorder	0.000297	0.00533	CbGeAlD
Paroxetine—HTR2A—cerebellum—bipolar disorder	0.000279	0.00502	CbGeAlD
Paroxetine—CYP2B6—brain—bipolar disorder	0.000278	0.005	CbGeAlD
Paroxetine—CYP2D6—nervous system—bipolar disorder	0.00027	0.00486	CbGeAlD
Paroxetine—CYP2D6—cerebellum—bipolar disorder	0.000254	0.00457	CbGeAlD
Paroxetine—ABCB1—thyroid gland—bipolar disorder	0.000231	0.00416	CbGeAlD
Paroxetine—HTR2A—brain—bipolar disorder	0.000227	0.00408	CbGeAlD
Paroxetine—CYP2D6—brain—bipolar disorder	0.000207	0.00371	CbGeAlD
Paroxetine—ABCB1—nervous system—bipolar disorder	0.000194	0.0035	CbGeAlD
Paroxetine—ABCB1—cerebellum—bipolar disorder	0.000183	0.00329	CbGeAlD
Paroxetine—ABCB1—brain—bipolar disorder	0.000149	0.00267	CbGeAlD
Paroxetine—HTR2A—Signaling by GPCR—ADCY2—bipolar disorder	1.68e-05	0.000147	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AKR1C4—bipolar disorder	1.68e-05	0.000147	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—ADCY2—bipolar disorder	1.67e-05	0.000146	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—ADCY2—bipolar disorder	1.67e-05	0.000146	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—TSHB—bipolar disorder	1.67e-05	0.000146	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CACNB2—bipolar disorder	1.67e-05	0.000146	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—TPH2—bipolar disorder	1.67e-05	0.000146	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—DRD2—bipolar disorder	1.67e-05	0.000146	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AKR1C4—bipolar disorder	1.67e-05	0.000146	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—HTR2C—bipolar disorder	1.66e-05	0.000145	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—DRD1—bipolar disorder	1.66e-05	0.000145	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—DRD2—bipolar disorder	1.66e-05	0.000145	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—ADCY2—bipolar disorder	1.65e-05	0.000144	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—DRD2—bipolar disorder	1.65e-05	0.000144	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—HTR2A—bipolar disorder	1.65e-05	0.000144	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HTR1A—bipolar disorder	1.64e-05	0.000144	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—DPYD—bipolar disorder	1.64e-05	0.000143	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—DRD2—bipolar disorder	1.64e-05	0.000143	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TAC1—bipolar disorder	1.62e-05	0.000141	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NTRK2—bipolar disorder	1.61e-05	0.000141	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—SLC6A3—bipolar disorder	1.61e-05	0.000141	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—DRD3—bipolar disorder	1.6e-05	0.00014	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—NR1D1—bipolar disorder	1.6e-05	0.00014	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—GSK3A—bipolar disorder	1.6e-05	0.00014	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—ADCY2—bipolar disorder	1.6e-05	0.00014	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HTR2C—bipolar disorder	1.59e-05	0.000139	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—DRD1—bipolar disorder	1.59e-05	0.000139	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—DRD4—bipolar disorder	1.56e-05	0.000136	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NTRK2—bipolar disorder	1.54e-05	0.000135	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—DRD3—bipolar disorder	1.54e-05	0.000134	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—NCAN—bipolar disorder	1.53e-05	0.000134	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—GSK3A—bipolar disorder	1.53e-05	0.000134	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CACNA1C—bipolar disorder	1.52e-05	0.000133	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—POMC—bipolar disorder	1.51e-05	0.000132	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TRPC3—bipolar disorder	1.51e-05	0.000132	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—NR1D1—bipolar disorder	1.51e-05	0.000132	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TRPC3—bipolar disorder	1.5e-05	0.000131	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—SLC5A3—bipolar disorder	1.5e-05	0.000131	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TRPC3—bipolar disorder	1.5e-05	0.000131	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—NR1D1—bipolar disorder	1.5e-05	0.000131	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—DRD4—bipolar disorder	1.49e-05	0.00013	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PIK3C2A—bipolar disorder	1.49e-05	0.00013	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TRPC3—bipolar disorder	1.48e-05	0.00013	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CLOCK—bipolar disorder	1.47e-05	0.000129	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—ADCY2—bipolar disorder	1.47e-05	0.000128	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TCF7L2—bipolar disorder	1.46e-05	0.000128	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—DRD2—bipolar disorder	1.45e-05	0.000127	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—POMC—bipolar disorder	1.45e-05	0.000127	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—NCAN—bipolar disorder	1.44e-05	0.000126	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ADM—bipolar disorder	1.44e-05	0.000126	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ADM—bipolar disorder	1.43e-05	0.000125	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—TPH2—bipolar disorder	1.43e-05	0.000125	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—TSHB—bipolar disorder	1.43e-05	0.000125	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CACNB2—bipolar disorder	1.43e-05	0.000125	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—NCAN—bipolar disorder	1.43e-05	0.000125	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ADM—bipolar disorder	1.43e-05	0.000125	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ADM—bipolar disorder	1.42e-05	0.000124	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—SLC5A3—bipolar disorder	1.41e-05	0.000124	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—DPYD—bipolar disorder	1.41e-05	0.000123	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TSHB—bipolar disorder	1.41e-05	0.000123	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PDE4B—bipolar disorder	1.41e-05	0.000123	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TACR1—bipolar disorder	1.41e-05	0.000123	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—ADCY2—bipolar disorder	1.4e-05	0.000123	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—SLC5A3—bipolar disorder	1.4e-05	0.000122	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TCF7L2—bipolar disorder	1.4e-05	0.000122	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TACR1—bipolar disorder	1.4e-05	0.000122	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PDE4B—bipolar disorder	1.4e-05	0.000122	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TSHB—bipolar disorder	1.4e-05	0.000122	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TACR1—bipolar disorder	1.39e-05	0.000122	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TSHB—bipolar disorder	1.39e-05	0.000122	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PDE4B—bipolar disorder	1.39e-05	0.000122	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—DRD2—bipolar disorder	1.39e-05	0.000121	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PDE4B—bipolar disorder	1.38e-05	0.000121	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TSHB—bipolar disorder	1.38e-05	0.000121	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TACR1—bipolar disorder	1.38e-05	0.000121	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—POMC—bipolar disorder	1.37e-05	0.00012	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—SNAP25—bipolar disorder	1.33e-05	0.000116	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—POMC—bipolar disorder	1.32e-05	0.000115	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NTRK1—bipolar disorder	1.31e-05	0.000115	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CACNA1C—bipolar disorder	1.31e-05	0.000115	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—HTR2A—bipolar disorder	1.28e-05	0.000112	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3C2A—bipolar disorder	1.28e-05	0.000112	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—S100B—bipolar disorder	1.28e-05	0.000112	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—HTR2A—bipolar disorder	1.27e-05	0.000111	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—HTR2A—bipolar disorder	1.26e-05	0.00011	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NTRK1—bipolar disorder	1.26e-05	0.00011	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CLOCK—bipolar disorder	1.25e-05	0.000109	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—S100B—bipolar disorder	1.22e-05	0.000107	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—TSHB—bipolar disorder	1.21e-05	0.000106	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—TPH2—bipolar disorder	1.21e-05	0.000106	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CACNB2—bipolar disorder	1.21e-05	0.000106	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—DPYD—bipolar disorder	1.19e-05	0.000104	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—ADCY2—bipolar disorder	1.18e-05	0.000103	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—HTR1A—bipolar disorder	1.16e-05	0.000102	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—HTR2A—bipolar disorder	1.16e-05	0.000101	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HTR1A—bipolar disorder	1.16e-05	0.000101	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—HTR2A—bipolar disorder	1.16e-05	0.000101	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HTR1A—bipolar disorder	1.15e-05	0.000101	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—SNAP25—bipolar disorder	1.15e-05	0.0001	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TAC1—bipolar disorder	1.15e-05	0.0001	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—HTR2A—bipolar disorder	1.15e-05	0.0001	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HTR1A—bipolar disorder	1.14e-05	9.98e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TAC1—bipolar disorder	1.14e-05	9.95e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TAC1—bipolar disorder	1.14e-05	9.92e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NRG1—bipolar disorder	1.13e-05	9.85e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TAC1—bipolar disorder	1.12e-05	9.83e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—HTR2C—bipolar disorder	1.12e-05	9.81e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—DRD1—bipolar disorder	1.12e-05	9.81e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—DRD1—bipolar disorder	1.12e-05	9.76e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HTR2C—bipolar disorder	1.12e-05	9.76e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HTR2C—bipolar disorder	1.11e-05	9.73e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—DRD1—bipolar disorder	1.11e-05	9.73e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CACNA1C—bipolar disorder	1.11e-05	9.7e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—DRD1—bipolar disorder	1.1e-05	9.64e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HTR2C—bipolar disorder	1.1e-05	9.64e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NTRK2—bipolar disorder	1.09e-05	9.55e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—DRD3—bipolar disorder	1.09e-05	9.51e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NTRK2—bipolar disorder	1.09e-05	9.5e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CLOCK—bipolar disorder	1.08e-05	9.48e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NTRK2—bipolar disorder	1.08e-05	9.47e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—GSK3A—bipolar disorder	1.08e-05	9.46e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—DRD3—bipolar disorder	1.08e-05	9.45e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3C2A—bipolar disorder	1.08e-05	9.45e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NRG1—bipolar disorder	1.08e-05	9.43e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—DRD3—bipolar disorder	1.08e-05	9.42e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—GSK3A—bipolar disorder	1.08e-05	9.41e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—GSK3A—bipolar disorder	1.07e-05	9.38e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NTRK2—bipolar disorder	1.07e-05	9.37e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—DRD3—bipolar disorder	1.07e-05	9.33e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—POMC—bipolar disorder	1.07e-05	9.32e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—GSK3A—bipolar disorder	1.06e-05	9.29e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—TPH2—bipolar disorder	1.06e-05	9.24e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—TSHB—bipolar disorder	1.06e-05	9.24e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CACNB2—bipolar disorder	1.06e-05	9.24e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—DRD4—bipolar disorder	1.06e-05	9.23e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—DRD4—bipolar disorder	1.05e-05	9.18e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—DRD4—bipolar disorder	1.05e-05	9.15e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—DPYD—bipolar disorder	1.04e-05	9.09e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—DRD4—bipolar disorder	1.04e-05	9.06e-05	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—POMC—bipolar disorder	1.03e-05	8.96e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CLOCK—bipolar disorder	1.02e-05	8.93e-05	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—POMC—bipolar disorder	1.02e-05	8.92e-05	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—POMC—bipolar disorder	1.02e-05	8.89e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—HTR2A—bipolar disorder	1.02e-05	8.88e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—ADCY2—bipolar disorder	1.01e-05	8.86e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CLOCK—bipolar disorder	1.01e-05	8.85e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—COMT—bipolar disorder	1.01e-05	8.82e-05	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—POMC—bipolar disorder	1.01e-05	8.8e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—MAOA—bipolar disorder	1e-05	8.76e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—TSHB—bipolar disorder	9.96e-06	8.7e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CACNB2—bipolar disorder	9.96e-06	8.7e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—TPH2—bipolar disorder	9.96e-06	8.7e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ADCY2—bipolar disorder	9.94e-06	8.69e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TCF7L2—bipolar disorder	9.91e-06	8.66e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ADCY2—bipolar disorder	9.89e-06	8.64e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—TSHB—bipolar disorder	9.88e-06	8.63e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—TPH2—bipolar disorder	9.88e-06	8.63e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CACNB2—bipolar disorder	9.88e-06	8.63e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ADCY2—bipolar disorder	9.86e-06	8.61e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TCF7L2—bipolar disorder	9.85e-06	8.61e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—DRD2—bipolar disorder	9.84e-06	8.6e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TCF7L2—bipolar disorder	9.82e-06	8.58e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—DPYD—bipolar disorder	9.8e-06	8.56e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—DRD2—bipolar disorder	9.79e-06	8.55e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ADCY2—bipolar disorder	9.76e-06	8.53e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—DRD2—bipolar disorder	9.76e-06	8.52e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HTR2A—bipolar disorder	9.73e-06	8.5e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TCF7L2—bipolar disorder	9.73e-06	8.5e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—DPYD—bipolar disorder	9.72e-06	8.49e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—SNAP25—bipolar disorder	9.7e-06	8.48e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CACNA1C—bipolar disorder	9.67e-06	8.45e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—DRD2—bipolar disorder	9.66e-06	8.44e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3C2A—bipolar disorder	9.42e-06	8.23e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—POMC—bipolar disorder	9.32e-06	8.14e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—POMC—bipolar disorder	9.27e-06	8.1e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—POMC—bipolar disorder	9.24e-06	8.07e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—POMC—bipolar disorder	9.15e-06	7.99e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CACNA1C—bipolar disorder	9.11e-06	7.96e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CACNA1C—bipolar disorder	9.03e-06	7.89e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NTRK1—bipolar disorder	8.91e-06	7.78e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3C2A—bipolar disorder	8.88e-06	7.76e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NTRK1—bipolar disorder	8.86e-06	7.74e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NTRK1—bipolar disorder	8.83e-06	7.72e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3C2A—bipolar disorder	8.8e-06	7.69e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NTRK1—bipolar disorder	8.75e-06	7.64e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—POMC—bipolar disorder	8.69e-06	7.59e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—COMT—bipolar disorder	8.68e-06	7.59e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—S100B—bipolar disorder	8.66e-06	7.57e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—MAOA—bipolar disorder	8.62e-06	7.53e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—S100B—bipolar disorder	8.61e-06	7.53e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—S100B—bipolar disorder	8.59e-06	7.5e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ADCY2—bipolar disorder	8.59e-06	7.5e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—S100B—bipolar disorder	8.5e-06	7.43e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—SNAP25—bipolar disorder	8.45e-06	7.38e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—GSK3B—bipolar disorder	8.18e-06	7.15e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—MTHFR—bipolar disorder	8.16e-06	7.13e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—POMC—bipolar disorder	8.12e-06	7.09e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—INS—bipolar disorder	8.07e-06	7.05e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—SNAP25—bipolar disorder	7.96e-06	6.96e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—SNAP25—bipolar disorder	7.9e-06	6.9e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—GSK3B—bipolar disorder	7.84e-06	6.85e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—POMC—bipolar disorder	7.77e-06	6.79e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—INS—bipolar disorder	7.73e-06	6.75e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NRG1—bipolar disorder	7.64e-06	6.68e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NRG1—bipolar disorder	7.6e-06	6.64e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NRG1—bipolar disorder	7.58e-06	6.62e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NRG1—bipolar disorder	7.5e-06	6.56e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ADCY2—bipolar disorder	7.48e-06	6.54e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—COMT—bipolar disorder	7.35e-06	6.42e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—MAOA—bipolar disorder	7.3e-06	6.38e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ADCY2—bipolar disorder	7.05e-06	6.16e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—MTHFR—bipolar disorder	7.02e-06	6.13e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ADCY2—bipolar disorder	6.99e-06	6.1e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HTR2A—bipolar disorder	6.85e-06	5.99e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HTR2A—bipolar disorder	6.83e-06	5.97e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HTR2A—bipolar disorder	6.77e-06	5.91e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—POMC—bipolar disorder	6.53e-06	5.7e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—INS—bipolar disorder	6.49e-06	5.67e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—COMT—bipolar disorder	6.41e-06	5.6e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—MAOA—bipolar disorder	6.36e-06	5.56e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—COMT—bipolar disorder	6.04e-06	5.27e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—MAOA—bipolar disorder	5.99e-06	5.24e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—COMT—bipolar disorder	5.98e-06	5.23e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—MTHFR—bipolar disorder	5.94e-06	5.19e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—MAOA—bipolar disorder	5.94e-06	5.19e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—POMC—bipolar disorder	5.61e-06	4.9e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—INS—bipolar disorder	5.58e-06	4.88e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—GSK3B—bipolar disorder	5.55e-06	4.85e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—GSK3B—bipolar disorder	5.52e-06	4.82e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—POMC—bipolar disorder	5.5e-06	4.81e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—GSK3B—bipolar disorder	5.5e-06	4.81e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—POMC—bipolar disorder	5.47e-06	4.78e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—INS—bipolar disorder	5.47e-06	4.78e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—POMC—bipolar disorder	5.46e-06	4.77e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—GSK3B—bipolar disorder	5.45e-06	4.76e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—INS—bipolar disorder	5.44e-06	4.76e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—INS—bipolar disorder	5.43e-06	4.74e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—POMC—bipolar disorder	5.4e-06	4.72e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—INS—bipolar disorder	5.37e-06	4.69e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—MTHFR—bipolar disorder	5.18e-06	4.52e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—MTHFR—bipolar disorder	4.88e-06	4.26e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—MTHFR—bipolar disorder	4.84e-06	4.23e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—POMC—bipolar disorder	4.75e-06	4.15e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—INS—bipolar disorder	4.73e-06	4.13e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—POMC—bipolar disorder	4.14e-06	3.62e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—INS—bipolar disorder	4.12e-06	3.6e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—POMC—bipolar disorder	3.9e-06	3.41e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—INS—bipolar disorder	3.88e-06	3.39e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—POMC—bipolar disorder	3.87e-06	3.38e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—INS—bipolar disorder	3.85e-06	3.36e-05	CbGpPWpGaD
